ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer

Que, Yi; Wang, Juan; Zhu, Jia; Li, Na; Huang, Junting; Lu, Suying; Sun, Feifei; Zhang, Lian; Zhen, Zijun; Zhang, Li; Cai, Ruiqing; Guo, Haixia*; Sun, Xiaofei*; Zhang, Yizhuo*南方医科大学; 中山大学
Frontiers in Immunology2021-7-6DOI: 10.3389/fimmu.2021.647733
5被引6阅读
引用收藏
分享

摘要

There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in two Chinese expert centers. The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR). Secondary objectives included characterizing toxicities. Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months). PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively. However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study. We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma. There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity. The Grade >= 3 TRAEs were attributed to the combination chemotherapy.

学科与关键词

关键词
PD-1 antibodypediatric cancermonotherapycombinationPD-L1
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2021-07-06
卷期
第 12 卷
页码
647733
DOI
10.3389/fimmu.2021.647733
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Key Technology Research Project of Guangzhou Science, Technology and Innovation Committee [201902020001]; Guangzhou Science and Technology project [201905010004]; National Scientific Foundation of China [82002835]

作者

  • Q

    Que, Yi (第一作者)

    sun yat sen univ

  • W

    Wang, Juan

    sun yat sen univ

查看全部 14 位作者收起作者
  • Z

    Zhu, Jia

    sun yat sen univ

  • L

    Li, Na

    southern med univ

  • H

    Huang, Junting

    sun yat sen univ

  • L

    Lu, Suying

    sun yat sen univ

  • S

    Sun, Feifei

    sun yat sen univ

  • Z

    Zhang, Lian

  • Z

    Zhen, Zijun

    sun yat sen univ

  • Z

    Zhang, Li

  • C

    Cai, Ruiqing

    sun yat sen univ

  • G

    Guo, Haixia (通讯)

    southern med univ

  • S

    Sun, Xiaofei (通讯)

    sun yat sen univ

  • Z

    Zhang, Yizhuo (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417